Morgan Stanley set a $42.00 price target on Valeant Pharmaceuticals International Inc. (NYSE:VRX) in a research report sent to investors on Tuesday morning. The firm currently has a a buy rating on the specialty pharmaceutical company’s stock.

Several other research firms also recently weighed in on VRX. TD Securities reaffirmed a hold rating and issued a $38.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Sunday, July 17th. Mizuho reaffirmed an underperform rating on shares of Valeant Pharmaceuticals International in a research note on Sunday, July 17th. Wells Fargo & Co. reaffirmed a sell rating and issued a $19.50 price objective on shares of Valeant Pharmaceuticals International in a research note on Sunday, July 17th. Rodman & Renshaw reaffirmed a buy rating and issued a $90.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Sunday, July 17th. Finally, Piper Jaffray Cos. set a $22.00 price objective on Valeant Pharmaceuticals International and gave the company a sell rating in a research note on Friday, August 19th. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Valeant Pharmaceuticals International presently has a consensus rating of Hold and a consensus price target of $40.18.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Shares of Valeant Pharmaceuticals International (NYSE:VRX) opened at 16.82 on Tuesday. The stock’s market cap is $5.85 billion. The firm has a 50-day moving average price of $22.29 and a 200-day moving average price of $25.33. Valeant Pharmaceuticals International has a 52-week low of $13.77 and a 52-week high of $119.87.

Valeant Pharmaceuticals International (NYSE:VRX) last issued its earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $1.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.78 by $0.23. The business had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.49 billion. Valeant Pharmaceuticals International had a positive return on equity of 41.02% and a negative net margin of 22.17%. The business’s quarterly revenue was down 11.0% on a year-over-year basis. During the same period last year, the company posted $2.74 earnings per share. On average, analysts anticipate that Valeant Pharmaceuticals International will post $6.45 EPS for the current fiscal year.

Large investors have recently modified their holdings of the company. BlackRock Group LTD acquired a new stake in shares of Valeant Pharmaceuticals International during the first quarter worth about $3,340,000. AXA raised its position in Valeant Pharmaceuticals International by 19.6% in the first quarter. AXA now owns 40,063 shares of the specialty pharmaceutical company’s stock worth $1,055,000 after buying an additional 6,568 shares in the last quarter. HBK Investments L P purchased a new position in Valeant Pharmaceuticals International during the first quarter worth $3,260,000. Allen Investment Management LLC raised its position in Valeant Pharmaceuticals International by 4.1% in the first quarter. Allen Investment Management LLC now owns 12,411 shares of the specialty pharmaceutical company’s stock worth $326,000 after buying an additional 493 shares in the last quarter. Finally, Legal & General Group Plc raised its position in Valeant Pharmaceuticals International by 2.8% in the first quarter. Legal & General Group Plc now owns 1,209,137 shares of the specialty pharmaceutical company’s stock worth $31,830,000 after buying an additional 33,247 shares in the last quarter. Hedge funds and other institutional investors own 64.39% of the company’s stock.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.